Read by QxMD icon Read

Therapeutic Delivery

(no author information available yet)
No abstract text is available yet for this article.
March 13, 2017: Therapeutic Delivery
Gerald K Schalau, Robert O Huber, Linda S Nartker, Xavier Thomas
No abstract text is available yet for this article.
February 6, 2017: Therapeutic Delivery
Peter Timmins
No abstract text is available yet for this article.
April 2017: Therapeutic Delivery
Hidetoshi Arima, Keiichi Motoyama, Taishi Higashi
Despite the recent approval of some gene medicines and nucleic acid drugs, further improvement of delivery techniques for these drugs is strongly required. Several delivery technologies for these drugs have been developed, in other words, viral and two types of nonviral (lipofection and polyfection) vectors. Among the polyfection system, the potential use of various cyclodextrin (CyD) derivatives and CyD-appended polymers as carriers for gene and nucleic acid drugs has been demonstrated. The polyamidoamine dendrimer (G3) conjugates with α-CyD (α-CDE (G3)) have been reported to possess noteworthy properties as DNA and nucleic acid drugs carriers...
April 2017: Therapeutic Delivery
Sameer Bhandari, Vikas Rana, Ashok K Tiwary
AIM: The low aqueous solubility of artemether and lumefantrine makes them less bioavailable. It is expected that by formulating self-microemulsifying drug-delivery systems (SMEDDS), their aqueous solubility and absorption will thus be enhanced. Results & methodology: Optimized liquid SMEDDS containing artemether and lumefantrine was adsorbed on Neusilin US2(®) employing spray drying technique to convert it into solid SMEDDS. Almost 90% of both drugs were released within 15 min in their respective official dissolution media...
April 2017: Therapeutic Delivery
Maria-Eleni Kyriazi, Amelie Heuer-Jungemann, Antonios G Kanaras
No abstract text is available yet for this article.
April 2017: Therapeutic Delivery
Vibhuti Agrahari, Vivek Agrahari, Ashim K Mitra
No abstract text is available yet for this article.
April 2017: Therapeutic Delivery
Narendar Dudhipala, Kishan Veerabrahma
Candesartan cilexetil (CC), an antihypertensive drug, has low oral bioavailability due to poor solubility and hepatic first-pass metabolism. These are major limitations in oral delivery of CC. Several approaches are known to reduce the problems of solubility and improve the bioavailability of CC. Among various approaches, nanotechnology-based delivery of CC has potential to overcome the challenges associated with the oral administration. This review focuses on various nano-based delivery systems available and tried for improving the aqueous solubility, dissolution and consequently bioavailability of CC upon oral administration...
February 2017: Therapeutic Delivery
Serena Mazzucchelli, Fabio Corsi
No abstract text is available yet for this article.
February 2017: Therapeutic Delivery
Iain Simpson
This Industry Update covers the period from 1 October through to 31 October 2016, and is based on information sourced from company press releases, scientific literature, patents and various news websites. The month saw several news items covering drug-delivery devices, including a new sensor to monitor and support the use of inhalers; launch in the UK of a new autoinjector for Cimzia(®), UCB's rheumatoid arthritis drug; and approval of Roche's Lucentis(®) in a prefilled syringe. Research was also published to show the value of continuous blood pressure monitoring in dementia management...
February 2017: Therapeutic Delivery
Chase S Linsley, Benjamin M Wu
The convergence of wearable sensors and personalized medicine enhance the ability to sense and control the drug composition and dosage, as well as location and timing of administration. To date, numerous stimuli-triggered smart drug-delivery systems have been developed to detect changes in light, pH, temperature, biomolecules, electric field, magnetic field, ultrasound and mechanical forces. This review examines the major advances within the last 5 years for the three most common light-responsive drug delivery-on-demand strategies: photochemical, photoisomerization and photothermal...
February 2017: Therapeutic Delivery
Teófilo Vasconcelos, Sara Marques, Bruno Sarmento
The increasing number of new chemical entities is bringing new challenges to the field of drug delivery. These drugs present bioavailability issues that are frequently associated with intestinal metabolism or efflux mechanisms. Some excipients, particularly surfactants, have demonstrated a capacity to interfere with these mechanisms, improving drug bioavailability. Consequently, these excipients can no longer be considered as inert and should be subject to special considerations from a regulatory perspective...
February 2017: Therapeutic Delivery
Sarah Shigdar
No abstract text is available yet for this article.
February 2017: Therapeutic Delivery
Sunil Kumar Jena, Abhay T Sangamwar
No abstract text is available yet for this article.
January 2017: Therapeutic Delivery
Elaine Harris
The present industry update covers the period of 1-30 November 2016, with information sourced primarily from company press releases, regulatory and patent agencies, scientific literature and various news websites. There was positive news on the clinical trials front for both EyeNovia and Glaxo SmithKline, but this month also saw Innocol release disappointing Phase IIb results for its Cogenzia product. In regulatory news, it was announced that the US FDA indicated that EyeGate may use the 510(k) De Novo Path for their device, the Ocular Bandage Gel...
January 2017: Therapeutic Delivery
Haliza Katas, Chai Yi Wen, Muhammad Irfan Siddique, Zahid Hussain, Fatin Hanini Mohd Fadhil
AIM: Chitosan (CS) has been extensively studied as drug delivery systems for wound healing. Results/methodology: CS nanoparticles were loaded with curcumin (Cur) and DsiRNA against prostaglandin transporter gene and they were incorporated into 20 and 25% w/v Pluronic F-127. The gels were later analyzed for their rheology, gelation temperature (Tgel), morphology, drug incorporation and in vitro drug release. The particle size was in the range of 231 ± 17-320 ± 20 nm, depending on CS concentration...
January 2017: Therapeutic Delivery
Mohd Neyaz Ahsan, Priya Ranjan Prasad Verma
The present work focuses on preparing a solidified self nano-emulsifying drug-delivery system (S-SNEDDS) to improve the in vitro dissolution of rosuvastatin and to evaluate its antihyperlipidemic activity. Powder flow characterization demonstrated good flow properties. The drug-excipient compatibility study indicates no possible interaction. Transmission electron microscopy and scanning electron microscopy revealed nonaggregated, spherical nanosized globules. The globule-size analysis revealed droplet size in nanorange (∼100 nm)...
January 2017: Therapeutic Delivery
Nadia Passerini
Nadia Passerini is interviewed by Hannah Makin, Commission Editor. Nadia Passerini is Associate Professor of Pharmaceutical Technology at the University of Bologna (Bologna, Italy). She obtained the degree in Pharmaceutical Chemistry and Technology at the University of Bologna in 1992 and the PhD in Pharmaceutical Science in 1997. Her research focuses on the study of drug delivery systems, developing new technologies and new apparatus for the production of solid dosage forms (microparticles, granules and tablets), which can optimize the bioavailability of drugs according to the specific needs of the therapy...
January 2017: Therapeutic Delivery
Nirmal Marasini, Mariusz Skwarczynski, Istvan Toth
Most pathogens gain access to the human body and initiate systemic infections through mucosal sites. A large number of currently marketed licensed vaccines are parenterally administered; they generate strong systemic immunity but not mucosal immunity. Nasal vaccination is an appealing strategy for the induction of mucosal-specific immunity; however, its development is mostly challenged by several factors, such as inefficient antigen uptake, its rapid mucociliary clearance, size-restricted permeation across epithelial barriers and absence of safe human mucosal adjuvants...
January 2017: Therapeutic Delivery
Tarun Goswami
Tarun Goswami speaks to Hannah Makin, Commissioning Editor: Tarun Goswami obtained his BS (Pharmacy) in 2003 from Delhi University (India) and his PhD in Pharmaceutical Sciences in 2008 from the University of the Pacific (CA, USA). He currently works at Amneal Pharmaceuticals as a Formulation Scientist in the Transdermal Drug Delivery Group. Having published multiple abstracts and articles in the area of transdermal and oral mucosal drug delivery, his current interests include the development of drug products that are administered via alternate routes such as through the skin and oral mucosa...
January 2017: Therapeutic Delivery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"